In the BioHarmony Drug Report Database
Pegvisomant
Somavert (pegvisomant) is a protein pharmaceutical. Pegvisomant was first approved as Somavert on 2002-11-12. It is used to treat acromegaly in the USA. It has been approved in Europe to treat acromegaly. The pharmaceutical is active against growth hormone receptor.
Trade Name
|
Somavert |
|---|---|
Common Name
|
pegvisomant |
ChEMBL ID
|
CHEMBL1201515 |
Indication
|
acromegaly |
Drug Class
|
Pegylated compounds |
Image (chem structure or protein)
